Evidence map›Paper›PMID 32961441›Full record

ArticleRedox biology2020

Epigenetic regulation of miR-29a/miR-30c/DNMT3A axis controls SOD2 and mitochondrial oxidative stress in human mesenchymal stem cells.

Yi-Deun Jung, Seul-Ki Park, Dayeon Kang, Supyong Hwang, Myoung-Hee Kang, Seung-Woo Hong, Jai-Hee Moon, Jae-Sik Shin, Dong-Hoon Jin, Dalsan You and 5 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Dnmt3a-mediated hypermethylation of FoxO3 promotes redox imbalance during osteoclastogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yi-Deun JungAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea; Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
Seul-Ki ParkAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea; Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea; Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST), Daejeon, 34113, Republic of Korea.
Dayeon KangDepartment of Pharmaceutical Engineering, College of Medical Sciences, Soon Chun Hyang University, Asan, 31538, Republic of Korea.
Supyong HwangAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Myoung-Hee KangAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Seung-Woo HongAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Jai-Hee MoonAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Jae-Sik ShinAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Dong-Hoon JinDepartment of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Dalsan YouDepartment of Urology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Joo-Yong LeeAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Yun-Yong ParkAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Jung Jin HwangAsan Institute for Life Sciences, Asan Medical Center, Seoul, 05505, Republic of Korea.
Choung Soo KimDepartment of Urology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea.
Nayoung SuhDepartment of Pharmaceutical Engineering, College of Medical Sciences, Soon Chun Hyang University, Asan, 31538, Republic of Korea. Electronic address: nysuh@sch.ac.kr.
Asan Medical Center · KRUniversity of Ulsan · KRKorea Research Institute of Bioscience and Biotechnology · KRKorea University of Science and Technology · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of human mesenchymal stem cells (hMSCs) in clinical applications requires large-scale cell expansion prior to administration. However, the prolonged culture of hMSCs results in cellular senescence, impairing their proliferation and therapeutic potentials. To understand the role of microRNAs (miRNAs) in regulating cellular senescence in hMSCs, we globally depleted miRNAs by silencing the DiGeorge syndrome critical region 8 (DGCR8) gene, an essential component of miRNA biogenesis. DGCR8 knockdown hMSCs exhibited severe proliferation defects and senescence-associated alterations, including increased levels of reactive oxygen species (ROS). Transcriptomic analysis revealed that the antioxidant gene superoxide dismutase 2 (SOD2) was significantly downregulated in DGCR8 knockdown hMSCs. Moreover, we found that DGCR8 silencing in hMSCs resulted in hypermethylation in CpG islands upstream of SOD2. 5-aza-2'-deoxycytidine treatment restored SOD2 expression and ROS levels. We also found that these effects were dependent on the epigenetic regulator DNA methyltransferase 3 alpha (DNMT3A). Using computational and experimental approaches, we demonstrated that DNMT3A expression was regulated by miR-29a-3p and miR-30c-5p. Overexpression of miR-29a-3p and/or miR-30c-5p reduced ROS levels in DGCR8 knockdown hMSCs and rescued proliferation defects, mitochondrial dysfunction, and premature senescence. Our findings provide novel insights into hMSCs senescence regulation by the miR-29a-3p/miR-30c-5p/DNMT3A/SOD2 axis.

Indexed as

Mesenchymal Stem CellsMitochondriaOxidative StressDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AEpigenesis, GeneticGene Knockdown TechniquesHumansMicroRNAsRNA-Binding ProteinsSuperoxide DismutaseSuperoxide Dismutase 2DGCR8 protein, humanDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanMicroRNAsMIRN29a microRNA, humanMIRN30b microRNA, humanRNA-Binding ProteinsSuperoxide DismutaseSuperoxide Dismutase 2Cellular senescenceDNMT3AHuman mesenchymal stem cellsmicroRNAsMitochondrial oxidative stressSOD2

Identifiers

PMID32961441
PMCPMC7509080
OpenAlexW3084340512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.